0.00Open0.01Pre Close0 Volume69 Open Interest90.00Strike Price0.00Turnover4319.18%IV15.28%PremiumNov 22, 2024Expiry Date0.00Intrinsic Value100Multiplier-6DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0054Delta0.0026Gamma7808.00Leverage Ratio-30.1092Theta0.0000Rho42.05Eff Leverage0.0000Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet